John Rossi is currently Vice President and leads the Translational Medicine team at Syncopation Life Sciences. Prior to joining, John served as Senior Director of Translational Medicine and Head of Cell Therapy Clinical Pharmacology at Kite, a Gilead Company. While at Kite, John led translational activities supporting the clinical development and global approvals of YESCARTA® and TECARTUS® CAR T cell therapies. At Kite, John’s team also supported work focusing on the mechanistic understanding of engineered cell therapy products under strategic collaborations with the NCI and numerous leading academic institutions. Prior to Kite, he spent 13 years in oncology drug development at Amgen working with teams to identify novel biomarkers for hematologic and solid tumor drug development programs.